Introduction. Brain arginine 8-vasopressin (AVP), through the V1a- and V2-receptors, is essential for the maintenance of mean arterial pressure (MAP). Central AVP interacts with the components of the renin-angiotensin system, which participate in MAP regulation. This study aimed to determine the effects of V1a-, V2- and V1a/V2-AVP selective antagonists and AT1- and AT2-angiotensin II (Ang II) selective antagonists on the MAP induced by AVP injected into the medial septal area (MSA) of the brain.
Materials and methods. Male Holtzman rats with stainless steel cannulae implanted into the MSA were used in experiments. Direct MAP was recorded in conscious rats.
Results. AVP administration into the MSA caused a prompt and potent pressor response in a dose-dependent fashion. Pretreatment with the V1a- and V2-antagonists reduced, whereas prior injection of the V1a/V2-antagonist induced a decrease in the MAP that remained below the baseline. Both AT 1- and AT2-antagonists elicited a decrease, while simultaneous injections of two antagonists were more effective in decreasing the MAP induced by AVP.
Conclusion. These results indicate there is a synergism between the V1a- and V2-AVP and AT1and AT2-Ang II receptors in the MSA in the regulation of MAP.
Berecek KH, Mah SC, Baum P., Hofbauer KGCardiovascular effects of intracerebroventricular injection of vasopressin in unanaesthetized normotensive and DOCA-salt hypertensive rats. J Hypertens Suppl1984;2:29-31.
2.
Unger T., Rohmeiss P., Becker H., Ganten D., Lang RE, Petty M.Sympathetic activation following central vasopressin receptor stimulation in conscious rats. J Hypertens Suppl1984;2:25-7.
3.
Berecek KH, Olpe HR, Jones RS, Hofbauer KGMicroinjection of vasopressin into the locus coeruleus of conscious rats. Am J Physiol1984;247:675-81.
4.
Dorsa DM, Brot MD, Shewey LM, Meyers KM, Szot P., Miller MAInteraction of a vasopressin antagonist with vasopressin receptors in the septum of the rat brain. Synapse1988;2:205-11.
5.
Dorsa DM, Majumdar LA, Petracca FM, Baskin DG, Cornett LECharacterization and localization of 3H-arginine8-vasopressin binding to rat kidney and brain tissue. Peptides1983;4:699-706.
6.
Poulin P., Lederis K., Pittman QJSubcellular localization and characterization of vasopressin binding sites in the ventral septal area, lateral septum, and hippocampus of the rat brain . J Neurochem1988;50:889-98.
7.
Shewey LM, Boer GJ, Szot P., Dorsa DMRegulation of vasopressin receptors and phosphoinositide hydrolysis in the septum of heterozygous and homozygous Brattleboro rats. Neuroendocrinology1989;50:292-8.
8.
Shewey LM, Brot MD, Szot P., Dorsa DMEnhanced phosphoinositol hydrolysis in response to vasopressin in the septum of the homozygous Brattleboro rat. Brain Res1989;478:95-102.
9.
Shewey LM, Dorsa DMEnhanced binding of 3H-arginine8-vasopressin in the Brattleboro rat. Peptides1986;7:701-04.
10.
Berecek KH, Webb RL, Brody MJEvidence for a central role for vasopressin in cardiovascular regulation. Am J Physiol1983;244:852-9.
11.
Martin SM, Malkinson TJ, Veale WL, Pittman QJThe action of centrally administered arginine vasopressin on blood pressure in the conscious rabbit. Brain Res1985;348:137-45.
12.
Budzikowski A., Lon S., Paczwa P., Szczepanska-Sadowska E.Differential effects of V2 vasopressin agonist and antagonists on blood pressure regulation in normotensive (WKY) and spontaneously hypertensive (SHR) rats. J Auton Nerv Syst1992;39:87-95.
13.
Hasser EM, Bishop VSReflex effect of vasopressin after blockade of V1 receptors in the area postrema . Circ Res1990;67:265-71.
14.
Walker BR, Childs ME, Adams EMDirect cardiac effects of vasopressin: role of V1- and V2-vasopressinergic receptors. Am J Physiol1988;255:261-5.
15.
Serradeil-Le Gal C., Herbert JM, Delisee C. et al. Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells. Am J Physiol1995;268:404-10.
16.
Fernandes S. , Bruneval P., Hagege A., Heudes D., Ghostine S., Bouby N.Chronic V2 vasopressin receptor stimulation increases basal blood pressure and exacerbates deoxycorticosterone acetate-salt hypertension. Endocrinology2002;143:2759-66.
17.
Jöhren O., Imboden H., Häuser W., Maye I., Sanvitto GL, Saavedra JMLocalization of angiotensin-converting enzyme, angiotensin II, angiotensin II receptor subtypes, and vasopressin in the mouse hypothalamus. Brain Res1997;757:218-27.
18.
Tamura K., Yokoyama N., Sumida Y. et al. Tissue-specific changes of type 1 angiotensin II receptor and angiotensin-converting enzyme mRNA in angiotensinogen gene-knockout mice. J Endocrinol1999;160:401-08.
19.
Bunnemann B. , Fuxe K., Ganten D.The brain renin-angiotensin system: localization and general significance. J Cardiovasc Pharmacol1992;19:51-62.
20.
Jöhren O., Inagami T., Saavedra JMAT1A, AT1B and AT2 angiotensin II receptor subtypes in rat brain. Neuroreport1995;6:2549-52.
21.
Phillips MI , Sumners C.Angiotensin II in central nervous system physiology . Regul Pept1998;78:1-11.
22.
Leung KH, Smith RD, Timmermans BM, Chiu ATRegional distribution of the two subtypes of angiotensin II receptor in rat brain using selective nonpeptide antagonists. Neurosci Lett1991;123:95-8.
23.
Häuser W., Jöhren O., Saavedra JMCharacterization and distribution of angiotensin II receptor subtypes in the mouse brain. Eur J Pharmacol1998;348:101-14.
24.
Wright JW, Harding JWBrain angiotensin receptor subtypes in the control of physiological and behavioral responses. Neurosci Biobehav Rev1994;18:21-53.
25.
De Gasparo M. , Catt KJ, Inagami T., Wright JW, Unger T.International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev2000;52:415-72.
26.
Paxinos G., Watson C. (eds). The Rat Brain in Stereotaxic Coordinates. New York: Academic Press, 1986:264.
27.
Laszlo FA, Laszlo FJR, De Wied D.Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev1991;43:3-108.
28.
Jackson EK, Renin and angiotensin. In: Hardman JG, Limbird LE, Gilman AG (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: MacGraw-Hill , 1996:715-31.
29.
Yamamura Y. , Ogawa H., Chihara T. et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science1991;52:572-4.
30.
Mayinger B. , Hensen J.Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Exp Clin Endocrinol Diabetes1999;107:157-65.
31.
Koshimizu TA , Nasa Y., Tanoue A. et al. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci USA2006;103:7807-12.
32.
Burrell LM, Phillips PA, Stephenson JM, Risvanis J., Rolls KA, Johnston CIBlood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension1994;23:737-43.
Thibonnier M., Kilani A., Rahman M. et al. Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients. Hypertension1999;34:1293-300.
35.
Fujisawa G. , Ishikawa S., Tsuboi Y., Okada K., Saito T.Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney Int1993;44:19-23.
36.
Naitoh M., Suzuki H., Murakami M. et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol1994;267:2245-54.
37.
Tahara A., Saito M., Sugimoto T. et al. Pharmacological characterization of YM087, a potent nonpeptide human vasopressin V1A and V2 receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol1998;357:63-9.
38.
Yatsu T., Tomura Y., Tahara A. et al. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol1999;376:239-46.
39.
Udelson JE, Smith WB, Hendrix GH et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation2001;104:2417-23.
40.
Lenkei Z., Palkovits M., Corvol P., Llorens-Cortes C.Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. Front Neuroendocrinol1997;18: 383-439.
41.
Lon S., Szczepanska-Sadowska E., Szczypaczewska M.Evidence that centrally released arginine vasopressin is involved in central pressor action of angiotensin II. Am J Physiol1996;270:167-73.
42.
Han NL, Sim MKHypothalamic angiotensin receptor subtypes in normotensive and hypertensive rats. Am J Physiol1998;275:703-09.
43.
Shelat SG, Reagan LP, King JL, Fluharty SJ, Flanagan-Cato LMAnalysis of angiotensin type 2 receptors in vasopressinergic neurons and pituitary in the rat. Regul Pept1998;73:3-12.
44.
Li Z., Iwai M., Wu L. et al. Role of AT2 receptor in the brain in regulation of blood pressure and water intake. Am J Physiol Heart Circ Physiol2003;284:116-21.
